Table 1.
Status of saRNA vaccine clinical trials against infectious diseases.
| Vaccine | Target | Status | Sponsor | clinicaltrials.gov Identifier |
|---|---|---|---|---|
| ARCT-154-01 | SARS-CoV-2 | Phase 1/2/3 Active, not recruiting |
Vinbiocare Biotechnology Joint Stock Company | NCT05012943 |
| ARCT-165, ARCT-154, ARCT-021 | SARS-CoV-2 | Phase 1/2 Recruiting |
Arcturus Therapeutics, Inc. | NCT05037097 |
| saRNA-LNP based on VEEV | SARS-CoV-2 | Phase 1 Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) | NCT04776317 |
| LNP-nCOV saRNA-02 Vaccine | SARS-CoV-2 | Phase 1 Recruiting |
MRC/UVRI and LSHTM Uganda Research Unit | NCT04934111 |
| GRT-R912, GRT-R914, and GRT-R918 | SARS-CoV-2 | Phase 1 Recruiting |
Gritstone bio, Inc. | NCT05435027 |
| GRT-R910 | SARS-CoV-2 | Phase 1 Active, not recruiting |
Gritstone bio, Inc. | NCT05148962 |
| CoV2 SAM (LNP) | SARS-CoV-2 | Phase 1 Completed |
GlaxoSmithKline | NCT04758962 |
| AAHI-SC2, AAHI-SC3 | SARS-CoV-2 | Phase 1/2 Recruiting |
ImmunityBio, Inc. | NCT05370040 |
| ARCT-021 | SARS-CoV-2 | Phase 2 Terminated |
Arcturus Therapeutics, Inc. | NCT04668339 |
| PF-07852352, PF-07836391, PF-07836394, PF-07836395, PF-07836396, PF-07867246 |
Influenza | Phase 1 Recruiting |
Pfizer | NCT05227001 |